Assessing cardiotoxicity of a highly selective novel MCL1 inhibitor with iPSC-derived models
.png)
Expert Insights: From animal to iPSC-derived models, a new era in preclinical evaluation
Research highlights: Targeted Protein Degradation in Tauopathies
Case Study: Development of a human iPSC-derived ALS model
-1.png)
The status of drug discovery and development for Parkinson's disease
Uncovering ALS pathology and potential drug targets with in vitro iPSC models
Subscribe to our newsletter
Stay up to date on iPSC innovations, events and news.
